Aeglea BioTherapeutics reports Q2 EPS ($2.27) vs. (27c) last year

Reports Q2 revenue $688,000 vs. $625,000 last year. “With the acquisition of Spyre Therapeutics and concurrent financing, we are in a privileged position to create meaningful new medicines for patients with IBD and build an industry-leading development organization,” said Cameron Turtle, DPhil, COO of Aeglea. “Our pipeline of differentiated and potentially best-in-class IBD programs, including a4b7 and TL1A, combined with a strategy to investigate therapeutic combinations and precision medicine approaches, offers the possibility to transform the treatment of this chronic and debilitating disease.” “In parallel, we have made significant progress streamlining the organization with the sale of pegzilarginase and pivoting our operations and strategy around the new IBD assets,” said Jonathan Alspaugh, President and CFO of Aeglea. “We are working to rapidly advance our co-lead product candidates with an expectation of initiating clinical studies for both SPY001 and SPY002 in 2024.”